What Is Platinum-Resistant Ovarian Cancer?

Platinum-resistant ovarian cancer is disease that returns or keeps growing within six months of completing platinum-based chemotherapy, the backbone treatment for ovarian cancer. While most patients respond well to initial platinum drugs like carboplatin or cisplatin, roughly 70% eventually relapse, and a significant share of those relapses qualify as platinum-resistant.¹ The distinction matters enormously because it reshapes treatment options, expected outcomes, and the entire clinical conversation going forward.

How the Six-Month Clock Works

The concept dates back to 1992, when researchers first proposed dividing recurrent ovarian cancer into categories based on how long the disease stayed away after finishing platinum chemotherapy. The key dividing line is six months. If the cancer comes back or progresses within that window, it is considered platinum-resistant. If it recurs after six months, it falls into the platinum-sensitive category, meaning re-treatment with platinum has a reasonable chance of working again.²

Within the resistant group, there is a further distinction. Patients whose cancer progresses while they are still on platinum treatment, or whose tumors never responded in the first place, are classified as platinum-refractory. Those whose cancer initially responded but then returned between three and six months are considered platinum-resistant in the stricter sense. Both groups face limited platinum-based options, but the refractory patients tend to have the toughest road ahead.

A multicenter registry study from India found that among 367 women with newly diagnosed epithelial ovarian cancer treated with platinum-based chemotherapy, about 17% had primary platinum-resistant disease, meaning their cancer met the resistance criteria after their very first round of treatment.³ Many more patients initially respond well but develop resistance after subsequent treatments.

Why Platinum Drugs Work in the First Place

To understand resistance, it helps to know what platinum drugs are doing inside cancer cells. Cisplatin and carboplatin work by binding to the DNA inside cells and forming cross-links that prevent the DNA from being copied or repaired properly. When a cancer cell cannot fix its damaged DNA, it triggers a self-destruct process.⁴ This is effective because ovarian cancer cells, especially those with mutations in DNA repair genes like BRCA1 or BRCA2, are already bad at repairing themselves. Platinum drugs exploit that weakness.

The problem is that cancer cells are not static. Over time, some cells develop workarounds that let them survive platinum exposure. Those surviving cells then multiply, and the tumor that grows back is composed of cells that have effectively learned to dodge the drug. Resistance is not one trick but many, sometimes operating simultaneously in the same patient.

How Tumors Become Resistant

The biology behind platinum resistance involves several overlapping strategies the cancer cells use to survive. These can broadly be grouped into a few categories.

One major route is reduced drug uptake or increased drug removal. Platinum drugs enter cells through copper transport proteins. Changes in these transporters can limit how much platinum actually gets inside the cell, while other transporters can pump the drug back out before it reaches the DNA.⁵

Another strategy is drug inactivation. Cancer cells can ramp up production of molecules that bind to platinum and neutralize it before it reaches the DNA. Two of the main culprits are glutathione and metallothionein, both of which are sulfur-containing molecules that latch onto platinum and render it harmless. Ovarian cancer cells with high levels of these molecules are substantially harder to kill with cisplatin.⁶ Lab studies have shown that cells with extreme platinum resistance can have dramatically elevated glutathione levels compared to their sensitive counterparts.⁷

A third pathway involves improved DNA repair. If the cancer cell can fix the damage platinum causes, the drug loses its killing power. This is especially relevant in patients with BRCA mutations, where platinum works well precisely because those repair mechanisms are broken. In some cases, after treatment, the tumor acquires secondary mutations that restore the broken BRCA gene, essentially re-equipping itself with the repair tools that platinum was exploiting. These so-called reversion mutations have been detected in circulating DNA from patients with resistant disease.⁸

Beyond these mechanisms, epigenetic changes also play a role. These are modifications to how genes are read and expressed without changing the DNA sequence itself. Patterns of DNA methylation and changes in molecules that regulate gene activity can silence tumor-suppressing genes or activate survival pathways, pushing the cancer toward a resistant state.⁹ Researchers have described complex feedback loops involving multiple layers of epigenetic regulation that help stabilize resistance once it develops.¹⁰

Cancer Stem Cells and the Tumor Microenvironment

Not all cancer cells within a tumor are equally vulnerable to chemotherapy. A small population of cancer stem cells appears to be especially hardy. These cells can self-renew, lie dormant during treatment, and then regenerate the tumor after chemotherapy ends. Their ability to resist drugs and reboot tumor growth is considered a key driver of recurrence in ovarian cancer.¹¹ Lab models have shown that these stem cell populations can survive cisplatin treatment and give rise to new tumors that mirror the original.¹²

The tissue surrounding the tumor, known as the tumor microenvironment, also contributes to resistance. Immune cells called macrophages, which normally fight infection, can be co-opted by the tumor into a supportive role. Tumor-associated macrophages release signaling molecules that boost the cancer’s survival and ability to withstand chemotherapy.¹³ Low-oxygen conditions within the tumor can further worsen this problem. Research has shown that oxygen-deprived tumor cells can reprogram specific macrophage populations in ways that suppress the immune system’s ability to kill cancer cells, ultimately promoting the spread of the disease.¹⁴

Standard Treatment Options After Platinum Fails

Once ovarian cancer is classified as platinum-resistant, the treatment strategy shifts. Re-treating with platinum alone is generally considered unlikely to produce a meaningful response, so doctors turn to non-platinum chemotherapy drugs. The most commonly used single agents include pegylated liposomal doxorubicin, topotecan, gemcitabine, and weekly paclitaxel. Response rates with these drugs are modest. A randomized trial comparing pegylated liposomal doxorubicin with topotecan found overall response rates of about 20% and 17% respectively, with median overall survival just over a year in both groups.¹⁵ These numbers reflect the reality that platinum-resistant disease is inherently harder to treat.

That said, the situation is not as bleak as those headline numbers might suggest. Even among women classified as platinum-resistant, about a third respond to second-line chemotherapy, and among the subset re-treated with platinum-containing combinations, response rates have reached over 50%.¹⁶ The six-month cutoff, while clinically useful, is a somewhat arbitrary line, and individual biology varies.

Bevacizumab and Anti-Angiogenic Therapy

One of the more established additions to treatment in platinum-resistant disease is bevacizumab, a drug that blocks the growth of new blood vessels that tumors need to sustain themselves. The AURELIA trial, a major randomized study, showed that adding bevacizumab to single-agent chemotherapy roughly doubled the time before the cancer progressed, from about 3.4 months to 6.7 months. The response rate also more than doubled, from about 12% to 27%.¹⁷ The trial did not show a clear overall survival benefit, however.

Real-world data have painted a somewhat more optimistic picture, particularly for the combination of bevacizumab with paclitaxel. One large retrospective analysis found that patients receiving this combination had median overall survival of 14 months compared to 9 months with paclitaxel alone.¹⁸ The gap between clinical trial results and real-world outcomes is worth noting and likely reflects the messier, more varied populations treated outside of trials.

Mirvetuximab Soravtansine and Antibody-Drug Conjugates

The treatment landscape has shifted meaningfully with the arrival of mirvetuximab soravtansine, an antibody-drug conjugate approved for platinum-resistant ovarian cancer in patients whose tumors express a protein called folate receptor alpha. The drug works by using an antibody to deliver a potent cell-killing agent directly to cancer cells that display this protein on their surface, sparing normal cells to some degree.

The confirmatory MIRASOL trial compared mirvetuximab soravtansine against standard chemotherapy in patients with folate receptor alpha-positive, platinum-resistant disease. The results were striking by the standards of this disease. The response rate was about 42% with mirvetuximab soravtansine compared to 16% with standard chemotherapy. Median overall survival reached roughly 16.5 months versus about 12.75 months with chemotherapy.¹⁹ This was one of the first times a drug demonstrated a statistically significant overall survival advantage over chemotherapy in the platinum-resistant setting, which is a high bar that many drugs have failed to clear.²⁰

Researchers are now testing mirvetuximab soravtansine in combination with other drugs. An early-phase study combining it with the immune checkpoint inhibitor pembrolizumab showed a response rate of 31% with a median duration of response of 8 months among patients with platinum-resistant disease, including many who had already been through multiple treatment lines.²¹

Immunotherapy Alone Has Been Disappointing

Immune checkpoint inhibitors, which have transformed treatment for cancers like melanoma and lung cancer, have produced underwhelming results in platinum-resistant ovarian cancer when used on their own. Ovarian tumors tend to be less visible to the immune system than some other cancers, partly because they create a microenvironment that suppresses immune activity.

Combination strategies have shown more promise. The TOPACIO/KEYNOTE-162 trial tested the PARP inhibitor niraparib combined with pembrolizumab in recurrent ovarian cancer. Among the 62 patients with ovarian cancer in the study, the overall response rate was 18% with a disease control rate of 65%. The responses were seen regardless of platinum sensitivity, prior bevacizumab use, or BRCA mutation status, which suggests the combination might work through mechanisms that do not depend on the traditional predictive markers.²² Even so, 18% is not transformative, and the search for better immunotherapy strategies continues.

Drugs That Target DNA Repair Vulnerabilities

Since platinum resistance often involves enhanced DNA repair, researchers have been looking at drugs that attack repair pathways from different angles. One area of active investigation is ATR inhibitors, which block a protein that cells rely on when their DNA is under stress during replication. Early clinical evidence suggests that combining an ATR inhibitor like berzosertib with gemcitabine may be more effective than gemcitabine alone in platinum-resistant patients.²³

There is also interest in combining ATR inhibitors with PARP inhibitors. Preclinical work suggests these two drug classes may have a synergistic effect: ATR inhibitors prevent cells from pausing to repair their DNA, while PARP inhibitors block a separate repair pathway. Together, they could overwhelm cancer cells with DNA damage they cannot manage.²⁴ This approach is still in clinical trials, but the early rationale is compelling.

Why So Many Clinical Trials Have Failed

A frustrating pattern in platinum-resistant ovarian cancer is the high failure rate of late-stage clinical trials. A systematic review of phase III trials in this setting found that negative outcomes are common and likely stem from multiple factors. The definition of platinum resistance itself is inconsistent across trials, the comparator arms vary widely, and biomarkers that could help identify which patients are most likely to benefit from a given drug are underused in trial design.²⁵

This is a genuine problem for the field. Because platinum-resistant ovarian cancer is biologically heterogeneous, lumping all resistant patients together in a trial can dilute the signal from a drug that works well in a specific subgroup. The success of mirvetuximab soravtansine, which was tested specifically in patients whose tumors express folate receptor alpha, may point the way forward: selecting patients based on a measurable biological feature rather than just time since last platinum treatment.

The Platinum-Free Interval Is Not the Whole Story

One common misconception is that the six-month platinum-free interval perfectly predicts how a patient’s cancer will behave. In reality, the cutoff is a rough clinical heuristic, not a precise biological measurement. A patient who relapses at five months and one who relapses at seven months may have more biologically similar tumors than the classification suggests. And newer treatments like PARP inhibitors and bevacizumab, given as maintenance after the initial response, can artificially extend the platinum-free interval without necessarily changing the underlying biology of the tumor.²

Studies have shown that the initial platinum-free interval still carries real prognostic weight over multiple treatment lines.²⁶ But the field is increasingly recognizing that molecular and genomic profiling of the tumor may eventually be more useful than a calendar-based definition. Liquid biopsy approaches that analyze tumor DNA circulating in the blood are being explored as a way to track resistance in real time and potentially guide treatment decisions more precisely.²⁷

Managing Symptoms and Quality of Life

For patients living with platinum-resistant ovarian cancer, symptom management is a major part of the treatment picture. One of the most distressing complications is malignant bowel obstruction, which occurs when tumor deposits block the intestines. This is common in advanced disease and is often a signal that the cancer is progressing despite treatment.²⁸

Management of bowel obstruction in this setting frequently focuses on controlling symptoms rather than surgical intervention. Medical options include pain control, anti-nausea medications, steroids, and drugs that reduce intestinal secretions. When these are insufficient, tube-based drainage or stenting may be used for relief.²⁹ A study of patients with malignant bowel obstruction found that those who were able to receive chemotherapy after the episode had median overall survival of about 5 months, while those limited to supportive care alone had a median of about 45 days.³⁰

Ascites, the buildup of fluid in the abdomen, is another burden many patients face. A multi-institutional study of pressurized intraperitoneal aerosol chemotherapy (PIPAC), a technique that delivers chemotherapy directly into the abdominal cavity as a fine mist during a minimally invasive procedure, reported a clinical benefit rate of about 35% in the overall group of platinum-resistant and refractory patients. Median time to resolution of ascites was one treatment cycle, and median overall survival was 14 months.³¹ While PIPAC is not yet standard of care, the ability to address ascites quickly is meaningful for daily quality of life.

Monitoring With CA-125 Has Limits

CA-125 is the blood marker most commonly used to track ovarian cancer, and many patients watch their CA-125 numbers closely. But in the setting of resistant or recurrent disease, the marker has real limitations. A study comparing CA-125-based progression criteria with imaging-based assessments found notable disagreement between the two. Among patients whose CA-125 levels suggested progression, imaging confirmed it about 71% of the time. But among patients whose CA-125 levels did not suggest progression, imaging still showed disease worsening in roughly two-thirds of cases.³² A separate analysis similarly found that early changes in CA-125 levels were not fully predictive of imaging-confirmed responses.³³ In practical terms, this means a rising or falling CA-125 level should be interpreted alongside imaging rather than as a standalone verdict on whether treatment is working.